SCHEMBL5314819

SCHEMBL5314819

COc1ccc(Cl)cc1Nc1ncnc2ccsc12

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.58
SRC P12931 1/20 0.52
FLT1 P17948 3/20 0.50
KDR P35968 3/20 0.50
FGFR1 P11362 1/20 0.50
EPHB2 P29323 1/20 0.50
FLT4 P35916 1/20 0.50
LMNA P02545 1/20 0.48
EGFR P00533 4/20 0.46
PIP4K2C Q8TBX8 1/20 0.45
BRAF P15056 2/20 0.45
TNNI3K Q59H18 1/20 0.45
RAF1 P04049 1/20 0.45
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
STAT1 P42224 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5317272 0.86 HTT (0.54) FADS1FLT1KDREGFRPIP4K2C
SCHEMBL5317160 0.86 MEN1 (0.55) FADS1SRCKDRLMNAEGFR
SCHEMBL5463906 0.85 EGFR (0.49) FADS1SRCFLT1KDREGFR
SCHEMBL5313425 0.83 HTT (0.56) FADS1FLT1KDRLMNAEGFR
SCHEMBL5317150 0.83 EGFR (0.44) FADS1FLT1KDREGFRPIP4K2C
SCHEMBL5331005 0.81 CSNK2A1 (0.58) FADS1EGFRPIP4K2CBRAFTNNI3K
SCHEMBL5337350 0.80 EGFR (0.52) FADS1EPHB2EGFRMAPK1
SCHEMBL5314602 0.80 ALDH1A1 (0.54) LMNAPIP4K2CBRAFTNNI3KMAPK1
SCHEMBL3801686 0.80 KMT2A (0.67) FADS1SRCFLT1KDRFGFR1
SCHEMBL5333554 0.80 KMT2A (0.67) FADS1SRCLMNAEGFRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO claimed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO claimed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US claimed
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO disclosed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 FADS1 1782/4885SRC 1534/4885FLT1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.